The peptide revolution in obesity treatment is advancing rapidly, with pharmaceutical company Ascletis submitting two Investigational New Drug (IND) applications to the U.S. FDA for novel once-monthly obesity peptides. This development represents a significant evolution in the weight management landscape that has captured attention across the bodybuilding, biohacking, and longevity communities—areas where Tony Huge has extensively documented peptide experimentation and real-world applications.
According to a PR Newswire announcement, Ascletis has filed applications for ASC36, a peptide amylin receptor agonist administered once monthly, and ASC36_35 FDC, a co-formulation combining ASC36 with peptide GLP-1R/GIPR agonists. This marks a potential paradigm shift from the current generation of weekly obesity medications to extended-release formulations requiring just twelve injections per year.
Understanding the New Obesity Peptide Mechanisms
The peptide compounds submitted by Ascletis target multiple metabolic pathways simultaneously, reflecting the industry’s move toward multi-receptor agonism—a concept that Tony Huge and the Enhanced Labs platform have long discussed in the context of metabolic optimization and body recomposition.
ASC36: Amylin Receptor Agonist Technology
ASC36 functions as an amylin receptor agonist, a mechanism distinct from the GLP-1 receptor agonists that have dominated recent obesity treatment discussions. Amylin is a naturally occurring peptide hormone co-secreted with insulin from pancreatic beta cells. It plays crucial roles in glucose homeostasis by slowing gastric emptying, suppressing glucagon secretion, and promoting satiety through central nervous system pathways.
For bodybuilders and physique athletes familiar with insulin protocols—topics extensively covered in Tony Huge’s experimental documentation—amylin represents the other side of the metabolic coin. While insulin drives nutrient partitioning and anabolism, amylin modulates the rate and intensity of these processes, potentially offering more refined metabolic control.
The Triple-Agonist Approach: ASC36_35 FDC
The combination formulation ASC36_35 FDC represents an even more sophisticated approach, combining the amylin receptor agonist with GLP-1R/GIPR agonists. This triple-receptor targeting strategy mirrors the evolutionary trajectory seen with tirzepatide (Mounjaro/Zepbound), which targets both GLP-1 and GIP receptors, and represents the cutting edge of peptide-based metabolic intervention.
This multi-agonist approach aligns with principles often discussed in biohacking circles: that complex metabolic conditions like obesity require multi-pathway interventions rather than single-target solutions. The bodybuilding community has long understood this through “stacking” various compounds—though the pharmaceutical industry now applies similar logic through precision peptide engineering.
Key Takeaways
- Extended dosing intervals: Once-monthly administration could significantly improve compliance and reduce injection burden compared to current weekly obesity peptides
- Novel mechanism: Amylin receptor agonism offers a distinct pathway from GLP-1-based therapies, potentially with different side effect profiles
- Combination therapy: The triple-agonist formulation represents pharmaceutical validation of multi-pathway metabolic optimization
- Research phase: IND submission means these compounds are entering early clinical trials—commercial availability remains years away
- Implications for biohackers: New peptide mechanisms may eventually become available through research channels, following the pattern seen with previous obesity peptides
Tony Huge’s Perspective on Obesity Peptides
Tony Huge has extensively documented his experiences with various peptide protocols for body recomposition, fat loss, and metabolic optimization. His work through Enhanced Labs and social media platforms has often preceded mainstream pharmaceutical developments, with the bodybuilding and biohacking communities serving as real-world testing grounds for novel compounds.
The emergence of amylin receptor agonists and triple-agonist formulations validates many concepts Tony Huge has promoted: that peptides offer targeted metabolic interventions with potentially superior profiles compared to traditional pharmaceuticals, and that combination approaches often yield synergistic benefits beyond single-compound protocols.
While pharmaceutical companies pursue FDA approval through rigorous clinical trials, the research peptide community has already experimented with various GLP-1 agonists, GIP agonists, and related compounds through gray-market research chemical suppliers—a reality Tony Huge has openly discussed and documented.
Implications for Bodybuilding and Body Recomposition
For competitive bodybuilders and physique athletes, obesity peptides represent powerful tools for contest preparation and maintaining extremely lean body compositions. The ability to control appetite, enhance insulin sensitivity, and promote fat oxidation while preserving muscle mass makes these compounds attractive alternatives or additions to traditional cutting protocols.
Advantages Over Traditional fat loss compounds
Compared to stimulant-based fat burners, thyroid hormones, or other traditional bodybuilding fat loss agents, peptide-based approaches like amylin and GLP-1 agonists offer several potential advantages:
- Appetite suppression without central nervous system stimulation
- Improved glucose disposal and insulin sensitivity
- Potential cardiovascular benefits rather than cardiovascular stress
- Muscle-sparing effects through multiple mechanisms
- Lower likelihood of metabolic adaptation or rebound
Tony Huge’s experimental approach has often highlighted these advantages, documenting dramatic body composition changes achieved through peptide protocols while maintaining strength and muscle fullness—outcomes difficult to achieve with traditional cutting drugs.
The Once-Monthly Injection Innovation
The pharmaceutical industry’s push toward extended-release formulations addresses one of the primary barriers to peptide therapy adoption: injection frequency. While weekly injections represented an improvement over daily protocols, monthly administration could transform obesity treatment from an ongoing medical intervention into something resembling a birth control injection or quarterly TRT protocol.
For biohackers and self-experimenters, however, injection frequency has historically been less of a barrier. Many in Tony Huge’s audience already administer daily or multiple-daily injections of various peptides, growth factors, and hormones. The value of monthly formulations in this context lies more in the sustained peptide delivery technology itself—innovations that could eventually be applied to other compounds beyond obesity treatment.
Timeline and Availability Considerations
IND submission to the FDA represents the beginning of a lengthy clinical development process. These compounds will undergo Phase 1, 2, and 3 clinical trials over the coming years before potential FDA approval. For pharmaceutical-grade, prescription availability, patients and practitioners should expect a timeline of 4-7 years minimum.
However, the research peptide market has historically moved faster than pharmaceutical timelines. As these compounds progress through trials and data becomes available, research chemical suppliers may offer versions for experimental purposes—following the pattern seen with semaglutide, tirzepatide, and other obesity peptides that became available through research channels before or alongside pharmaceutical approval.
Tony Huge has consistently advocated for informed self-experimentation while acknowledging the risks inherent in using non-pharmaceutical-grade compounds. His documentation serves as both cautionary tale and practical guide for those choosing to explore cutting-edge peptides outside traditional medical channels.
Safety and Side Effect Considerations
While specific safety data for ASC36 and ASC36_35 remains limited pending clinical trials, amylin receptor agonism as a mechanism has been previously explored through pramlintide (Symlin), an approved diabetes medication. Common side effects of amylin agonists include nausea, reduced appetite, and gastrointestinal disturbances—similar to GLP-1 receptor agonists.
The combination formulation may present additive gastrointestinal effects given that all three receptor targets (amylin, GLP-1, and GIP) influence gastric emptying and appetite regulation. This underscores the importance of proper dosing titration—a principle Tony Huge emphasizes in his peptide protocols, typically advocating for starting at minimal effective doses and gradually escalating.
Conclusion
Ascletis’s submission of IND applications for ASC36 and ASC36_35 FDC represents another milestone in the rapidly evolving peptide obesity treatment landscape. These once-monthly formulations targeting amylin, GLP-1, and GIP receptors validate the multi-pathway approach to metabolic optimization that has long been discussed in bodybuilding and biohacking communities.
For followers of Tony Huge and the broader enhanced athletics community, these developments signal continued pharmaceutical innovation in areas where self-experimenters have already been exploring. As these compounds progress through clinical development, they will likely generate valuable safety and efficacy data while potentially becoming available through research channels for those willing to experiment outside traditional medical paradigms.
The convergence of pharmaceutical peptide development and the biohacking community’s appetite for cutting-edge metabolic interventions ensures that compounds like ASC36 will remain closely watched by anyone serious about body composition optimization, longevity, and pushing the boundaries of human performance.